Institutional money kept flowing into Intuitive Surgical during the third quarter of 2026, even as Wall Street’s price targets drifted lower. Krilogy Financial raised its stake by 79.9% over the period, while Salem added 1.2% — two very different tempos, but the same direction. The filings, disclosed today, capture positions as they stood at quarter-end; they are not evidence of trades executed in response to fresh news.
That distinction matters, because the more consequential developments are elsewhere. Institutions already control 83.64% of the medical-device maker’s shares, so the latest additions merely reinforce an ownership base that was heavily institutional to begin with.
Analysts Stay Bullish, but the Targets Are Slipping
Consensus among the sell-side remains constructive. A poll of 31 analysts yields a moderately positive buy recommendation, with an average twelve-month price target of $498.83. The majority favor buying, though the mix includes neutral ratings and a single sell — a friendly consensus, not a unanimous one. And a mean target is an expectation, not a promise.
Recent revisions tell a subtler story. BTIG Research trimmed its target from $469 to $454 on Monday while keeping its buy rating, an adjustment made within a broader third-quarter outlook on the medical-technology sector. Citigroup cut its target from $590 to $500, also maintaining a buy. Barclays, for its part, initiated coverage on October 7 with an Overweight rating and a $485 target — above BTIG’s revised figure. The takeaway: positive recommendations do not imply static valuation assumptions.
Guthart Lays Out a Broader Shanghai Play
On Sunday, Executive Chair Gary S. Guthart detailed how Intuitive Surgical intends to deepen its Shanghai footprint. His remarks covered clinical training, relationships with Chinese companies along the supply chain, and collaboration on digitization and artificial intelligence. That scope goes well beyond a product showcase — training and supply-chain ties sit alongside technology partnerships, which is the right frame for judging the expansion plans.
Should investors sell immediately? Or is it worth buying Intuitive Surgical?
Come November, the company plans to present da Vinci 5 and da Vinci SP at the China International Import Expo. The exhibition is a planned step, not a completed one.
The Fundamentals Already on the Table
Second-quarter 2026 results give the more concrete anchor. Earnings per share came in at $2.80 against expectations of $2.48, and revenue reached $2.89 billion versus a $2.83 billion consensus — growth of 18.4% year over year. On top of that, a next-generation robotic endoscope for gastrointestinal procedures has been submitted to the FDA, though any market expansion hinges on approval.
October 20: The Next Hard Data Point
Media reports point to Intuitive Surgical releasing third-quarter 2026 results on October 20 after the market close. That date sets up a collision of time horizons: Shanghai describes the strategic arc, while the quarterly report supplies the near-term operational verdict. BTIG’s lower target, delivered before the print, already signals that a buy rating and an unchanged valuation framework are two different things. The institutional buying rounds out the picture — it does not substitute for the operational test ahead.
Ad
Intuitive Surgical Stock: Buy or Sell?! New Intuitive Surgical Analysis from October 14 delivers the answer:
The latest Intuitive Surgical figures speak for themselves: Urgent action needed for Intuitive Surgical investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 14.
Intuitive Surgical: Buy or sell? Read more here...
